Esmirtazapine
Esmirtazapine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | F33.9 | — | 5 | 2 | 2 | 3 | 11 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 2 | — | 7 | — | 10 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | 4 | 1 | — | 6 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 2 | 1 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 1 | 1 | — | 2 |
| Shivering | D012768 | — | — | — | 2 | — | 2 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 1 | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 2 | — | 2 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | 1 | 2 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | 1 | 1 | 2 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | F51.01 | 2 | 1 | 7 | — | 1 | 11 | |
| Neoplasms | D009369 | C80 | 1 | 3 | 2 | — | — | 5 | |
| Anorexia | D000855 | HP_0002039 | R63.0 | — | 3 | 1 | — | 1 | 5 |
| Sleep wake disorders | D012893 | G47 | — | — | 5 | — | — | 5 | |
| Dyssomnias | D020920 | — | — | 4 | — | — | 4 | ||
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | — | 1 | 1 | — | 1 | 3 |
| Dementia | D003704 | F03 | — | — | 2 | — | 1 | 3 | |
| Intrinsic sleep disorders | D020919 | F51.03 | — | — | 3 | — | — | 3 | |
| Treatment-resistant depressive disorder | D061218 | — | — | 1 | — | 1 | 2 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 1 | — | 1 | 2 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 4 | — | — | — | 4 |
| Vomiting | D014839 | HP_0002013 | R11.1 | 2 | 2 | — | — | — | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | — | 1 | 3 |
| Cocaine-related disorders | D019970 | F14 | 1 | 3 | — | — | — | 3 | |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 1 | — | — | 1 | 2 |
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | 1 | 2 | ||
| Hyperemesis gravidarum | D006939 | EFO_1000971 | O21 | 1 | 2 | — | — | — | 2 |
| Weight loss | D015431 | HP_0001824 | — | 1 | — | — | 1 | 2 | |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | 1 | |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | — | 6 | ||
| Cardiovascular abnormalities | D018376 | EFO_0003848 | 1 | — | — | — | — | 1 | |
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | 1 | 1 | ||
| Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
| Alcohol-related disorders | D019973 | F10 | — | — | — | — | 1 | 1 | |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | — | 1 | 1 | |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ESMIRTAZAPINE |
| INN | esmirtazapine |
| Description | Esmirtazapine (ORG-50,081) is a tetracyclic antidepressant drug which was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors.
|
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1 |
Identifiers
| PDB | — |
| CAS-ID | 61337-87-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1366933 |
| ChEBI ID | — |
| PubChem CID | 3085218 |
| DrugBank | DB06678 |
| UNII ID | 4685R51V7M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 34 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more